Anti-VLDL receptor monoclonal antibodies inhibit fibrin-VLDL receptor interaction and reduce fibrin-dependent leukocyte transmigration

Summary

Our previous studies revealed that the interaction of fibrin with the very low density lipoprotein receptor (VLDLR) promotes transendothelial migration of leukocytes and thereby inflammation, and localised the fibrin-binding site to CR-domains 2–4 of this receptor. In the present study, we tested interaction of three anti-VLDLR monoclonal antibodies, mAb 1H10, 1H5, and 5F3, with recombinant fragments of VLDLR containing various combinations of its CR-domains and found that the epitopes for mAb 1H10 and mAb 1H5 overlap with the fibrin-binding site of VLDLR. Based on these findings, we hypothesised that mAb 1H10 and mAb 1H5 should inhibit fibrin-VLDLR interaction and modulate leukocyte transmigration. To test this hypothesis, we first demonstrated that these monoclonal antibodies both have high affinity to the fibrin-binding fragments of the VLDL receptor and efficiently inhibit interaction between the VLDLR-binding fragment of fibrin and the fibrin-binding fragments of VLDLR. Next, in the in vitro experiments using leukocyte transendothelial migration assay we found that both monoclonal antibodies efficiently inhibit leukocyte transmigration induced by fibrin mimetic NDSK-II. Finally, in vivo experiments using mouse model of peritonitis revealed that mAb 1H10 and mAb 1H5 both significantly reduce infiltration of leukocytes into the peritoneum. Furthermore, our experiments using mouse model of myocardial ischemia-reperfusion injury revealed that both monoclonal antibodies significantly reduce myocardial injury induced by ischaemia-reperfusion. Thus, the results obtained indicate that monoclonal antibodies 1H10 and 1H5 are novel specific inhibitors of fibrin-VLDLR-dependent leukocyte transmigration pathway. They may represent potential therapeutics for treatment of fibrin-dependent inflammation including myocardial ischaemia-reperfusion injury.

Keywords

Fibrinogen/fibrin - VLDL receptor - leukocyte transmigration - monoclonal antibodies

• References

• 1 Clark RA. Fibrin and wound healing. Ann NY Acad Sci 2001; 936: 355-367.
• 2 Altieri DC. Regulation of leukocyte-endothelium interaction by fibrinogen. Thromb Haemost 1999; 82: 781-786.
• 3 Petzelbauer P, Zacharowski PA, Miyazaki Y. et al. The fibrin-derived peptide Bβ15-42 protects the myocardium against ischaemia-reperfusion injury. Nat Med 2005; 11: 298-304.
• 4 Yakovlev S, Mikhailenko I, Cao C. et al. Identification of VLDLR as a novel endothelial cell receptor for fibrin that modulates fibrin-dependent transendothelial migration of leukocytes. Blood 2012; 119: 637-644.
• 5 Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 03: 1894-1904.
• 6 Medved L, Weisel JW. on behalf of Fibrinogen and Factor XIII Subcommittee of Scientific Standardisation Committee of International Society on Thrombosis and Haemostasis. Recommendations for nomenclature on fibrinogen and fibrin. J Thromb Haemost 2009; 07: 355-359.
• 7 Blomback B, Blomback M, Henschen A. et al. N-terminal disulphide knot of human fibrinogen. Nature 1968; 218: 130-134.
• 8 Bach TL, Barsigian C, Yaen CH. et al. Endothelial cell VE-cadherin functions as a receptor for the β15-42 sequence of fibrin. J Biol Chem 1998; 273: 30719-30728.
• 9 Martinez J, Ferber A, Bach TL, Yaen CH. Interaction of fibrin with VE-cadherin. Ann NY Acad Sci 2001; 936: 386-405.
• 10 Gorlatov S, Medved L. Interaction of fibrin(ogen) with the endothelial cell receptor VE-cadherin: mapping of the receptor-binding site in the NH₂-terminal portions of the fibrin β chains. Biochemistry 2002; 41: 4107-4116.
• 11 Takahashi S, Kawarabayasi Y, Nakai T. et al. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci USA 1992; 89: 9252-9256.
• 12 Sakai J, Hoshino A, Takahashi S. et al. Structure, chromosome location, and expression of the human very low density lipoprotein receptor gene. J Biol Chem 1994; 269: 2173-2182.
• 13 Trommsdorff M, Gotthardt M, Hiesberger T. et al. Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell 1999; 97: 689-701.
• 14 Herz J, Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci 2006; 07: 850-859.
• 15 Hembrough TA, Ruiz JF, Swerdlow BM. et al. Identification and characterisation of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity. Blood 2004; 103: 3374-3380.
• 16 Takahashi S, Sakai J, Fujino T. et al. The very low-density lipoprotein (VLDL) receptor: characterisation and functions as a peripheral lipoprotein receptor. J Atheroscler Thromb 2004; 11: 200-208.
• 17 Lillis AP, Van Duyn LB, Murphy-Ullrich JE. et al. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 2008; 88: 887-918.
• 18 Ruiz J, Kouiavskaia D, Migliorini M. et al. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J Lipid Res 2005; 46: 1721-1731.
• 19 Yakovlev S, Medved L. Interaction of fibrin with the very low density lipoprotein receptor: Further characterisation and localisation of the fibrin-binding site. Biochemistry 2015; 54: 4751-4761.
• 20 Yakovlev S, Gao Y, Cao C. et al. Interaction of fibrin with VE-cadherin and anti-inflammatory effect of fibrin-derived fragments. J Thromb Haemost 2011; 09: 1847-1855.
• 21 Williams SE, Ashcom JD, Argraves WS. et al. A novel mechanism for controlling the activity of α₂-macroglobulin receptor/low density lipoprotein receptor-related protein. Multiple regulatory sites for 39-kDa receptor-associated protein. J Biol Chem 1992; 267: 9035-9040.
• 22 Collins SJ, Ruscetti FW, Gallagher RE. et al. Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci USA 1978; 75: 2458-2462.
• 23 Cao C, Lawrence DA, Strickland DK. et al. A specific role of integrin Mac-1 in accelerated macrophage efflux to the lymphatics. Blood 2005; 106: 3234-3241.
• 24 Hauert AB, Martinelli S, Marone C. et al. Differentiated HL-60 cells are a valid model system for the analysis of human neutrophil migration and chaemotaxis. Int J Biochem Cell Biol 2002; 34: 838-854.
• 25 Herz J, Goldstein JL, Strickland DK. et al. 39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/α₂-macroglobulin receptor. J Biol Chem 1991; 266: 21232-21238.
• 26 Yakovlev S, Gorlatov S, Ingham K. et al. Interaction of fibrin(ogen) with heparin: further characterisation and localisation of the heparin-binding site. Biochemistry 2003; 42: 7709-7716.